Gene: RPL3L

6123
-
ribosomal protein L3 like
protein-coding
16p13.3
Ensembl:ENSG00000140986 MIM:617416 Vega:OTTHUMG00000128685 UniprotKB:Q92901
NC_000016.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.638e-1 (AD)  6.177e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs2252523chr16:1947613 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MB0.634
CKM0.591
MYOZ10.585
TNNI10.584
MYLPF0.576
XIRP20.555
TNNC10.553
MYH20.548
MYL10.544
ENO30.543

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TRPV6-0.405
SLC30A3-0.401
CALHM1-0.384
LYZL4-0.383
RHOF-0.379
MICAL2-0.378
KCNC3-0.378
RTN4RL2-0.378
RTP1-0.378
RHO-0.376

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of RPL3L mRNA"18648102
D001194AsbestosAsbestos results in increased expression of RPL3L mRNA22398240
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of RPL3L mRNA22228805
C006780bisphenol Abisphenol A affects the expression of RPL3L mRNA25181051
C006780bisphenol Abisphenol A results in decreased expression of RPL3L mRNA27178563
D006108GraphiteGraphite results in increased expression of RPL3L mRNA27440207
C412815GW 4064GW 4064 results in decreased expression of RPL3L mRNA26655953
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of RPL3L mRNA26752646
D007854LeadLead results in decreased expression of RPL3L mRNA19921347
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RPL3L mRNA27935865
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of RPL3L mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of RPL3L mRNA25729387
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of RPL3L mRNA27935865
D011441PropylthiouracilPropylthiouracil results in increased expression of RPL3L mRNA24780913
D053260SootSoot results in increased expression of RPL3L mRNA26551751
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of RPL3L mRNA25729387
D014227TriazinesTriazines inhibits the reaction [IDH2 protein mutant form results in decreased expression of RPL3L mRNA]27469509
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate results in decreased expression of RPL3L mRNA29024780
D014520UrethaneUrethane results in increased expression of RPL3L mRNA28818685
D014635Valproic AcidValproic Acid results in increased methylation of RPL3L gene29154799

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-TAS8921388  
GO:0003735structural constituent of ribosome-IBA21873635  
GO:0003735structural constituent of ribosome-NAS12962325  
GO ID GO Term Qualifier Evidence PubMed
GO:0000027ribosomal large subunit assembly-IBA21873635  
GO:0006412translation-NAS12962325  
GO ID GO Term Qualifier Evidence PubMed
GO:0005840ribosome-TAS8921388  
GO:0016020membrane-HDA19946888  
GO:0022625cytosolic large ribosomal subunit-HDA12962325  
GO:0022625cytosolic large ribosomal subunit-IBA21873635  
KEGG ID KEGG Term
hsa03010Ribosome
Reactome ID Reactome Term Evidence
R-HSA-1266738Developmental BiologyIEA
R-HSA-1430728MetabolismIEA
R-HSA-156827L13a-mediated translational silencing of Ceruloplasmin expressionTAS
R-HSA-156842Eukaryotic Translation ElongationIEA
R-HSA-156902Peptide chain elongationIEA
R-HSA-1643685DiseaseTAS
R-HSA-168254Influenza InfectionTAS
R-HSA-168255Influenza Life CycleTAS
R-HSA-168273Influenza Viral RNA Transcription and ReplicationTAS
R-HSA-1799339SRP-dependent cotranslational protein targeting to membraneIEA
R-HSA-1799339SRP-dependent cotranslational protein targeting to membraneTAS
R-HSA-192823Viral mRNA TranslationTAS
R-HSA-2408522Selenoamino acid metabolismIEA
R-HSA-2408557Selenocysteine synthesisIEA
R-HSA-376176Signaling by ROBO receptorsIEA
R-HSA-392499Metabolism of proteinsTAS
R-HSA-392499Metabolism of proteinsIEA
R-HSA-422475Axon guidanceIEA
R-HSA-5663205Infectious diseaseTAS
R-HSA-6791226Major pathway of rRNA processing in the nucleolus and cytosolTAS
R-HSA-71291Metabolism of amino acids and derivativesIEA
R-HSA-72312rRNA processingTAS
R-HSA-72613Eukaryotic Translation InitiationTAS
R-HSA-72689Formation of a pool of free 40S subunitsTAS
R-HSA-72706GTP hydrolysis and joining of the 60S ribosomal subunitTAS
R-HSA-72737Cap-dependent Translation InitiationTAS
R-HSA-72764Eukaryotic Translation TerminationIEA
R-HSA-72766TranslationTAS
R-HSA-72766TranslationIEA
R-HSA-8868773rRNA processing in the nucleus and cytosolTAS
R-HSA-8953854Metabolism of RNATAS
R-HSA-9010553Regulation of expression of SLITs and ROBOsIEA
R-HSA-927802Nonsense-Mediated Decay (NMD)TAS
R-HSA-975956Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)TAS
R-HSA-975957Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal